Hao et al. [43] noted overexpression of SPRR2D in early-stage prostate cancer, suggesting its role in advancing cancer severity, while Liao et al. [44] found FAM9C to significantly influence breast cancer prognosis, linking it to key pathways affecting tumor progression. This evidence concerns the gene SPRR2D and prostate carcinoma.